Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address	Total Patents
DADE BEHRING INC.	DEERFIELD, IL	1

International Classification(s)

• C12P:FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESI....
• C12Q:MEASURING OR TESTING PROCESSES INVOLVING ENZYMES O....
• G01N:INVESTIGATING OR ANALYSING MATERIALS BY DETERMININ....

• [Classification Symbol]

• [Patents Count]

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Huang, Grace P	Miami, FL	1	179
Rhode, Peter R	Miami, FL	10	290
Stinson, Jeffrey R	Davie, FL	24	380
Wong, Hing C	Ft. Lauderdale, FL	69	571

Cited Art Landscape

Patent Info	(Count)	# Cites	Year
GGMJ TECHNOLOGIES, L.L.C. (1)
* 5,348,867 Expression of proteins on bacterial surface		67	1991
DYAX CORP. (1)
* 5,223,409 Directed evolution of novel binding proteins		1335	1991

* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info	(Count)	# Cites	Year
SOPHERION THERAPEUTICS, INC. (1)
* 2003/0235,864 Method to screen ligands using eukaryotic cell display		4	2003
WELLS FARGO CAPITAL FINANCE, LLC (1)
9,132,190 Therapeutic DLL4 binding proteins		0	2013
RAMOT AT TEL-AVIV UNIVERSITY LTD. (1)
* 6,165,722 Representations of bimolecular interactions		5	1999
ABBVIE DEUTSCHLAND GMBH & CO. KG (6)
8,906,864 Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use		0	2006
* 2009/0297,527 Binding Domains of Proteins of the Repulsive Guidance Molecule (RGM) Protein Family and Functional Fragments Thereof, and Their Use		7	2006
8,895,004 Method for the treatment of amyloidoses		0	2008
* 2010/0322,948 Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same		6	2008
9,175,075 Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein		0	2010
9,176,150 Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof		0	2011
Teva Pharmaceuticals Ausralia Pty Ltd (1)
9,127,057 Anti-IL-23 heterodimer specific antibodies		0	2011
ALEXION PHARMACEUTICALS, INC. (5)
9,011,852 Anti-C5a antibodies		4	2011
9,221,901 Methods of treating complement-associated disorders with anti-C5a antibodies		2	2015
9,309,310 Nucleic acids encoding anti-C5a antibodies		2	2015
9,371,378 Anti-C5a antibodies		1	2016
9,434,784 Nucleic acids encodng anti-C5A antibodies		0	2016
SERONO GENETICS INSTITUTE S.A. (1)
6,867,189 Use of adipsin/complement factor D in the treatment of metabolic related disorders		5	2002
GEORGETOWN UNIVERSITY (1)
* 7,355,015 Matriptase, a serine protease and its applications		2	2000
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (2)
7,041,441 Phage display of intact domains at high copy number		3	1997
* 2004/0265,315 Methods of preventing or treating T cell malignancies by administering CD2 antagonists		2	2003
NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (1)
9,181,553 Method of treatment of breast cancers over-expressing the SHP2 signature genes		0	2012
University of Hawaii (1)
9,244,074 Biomarker of asbestos exposure and mesothelioma		0	2012
DOMANTIS (1)
* 2003/0039,958 Direct screening method		7	2002
NEXUS DX, INC. (1)
* 5,981,249 Single-chain polypeptides comprising creatine kinase M and creatine kinase B		0	1998
COSMO TECHNOLOGIES LIMITED (2)
8,231,878 Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof		0	2009
* 2010/0310,560 Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof		3	2009
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (1)
7,611,858 Detection of cannabinoid receptor biomarkers and uses thereof		0	2007
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (1)
8,680,239 Use of RGM and its modulators		0	2012
YALE UNIVERSITY (2)
7,297,762 Modified avian pancreatic polypeptide miniature binding proteins		0	2001
7,495,070 Protein binding miniature proteins		0	2004
Bionomics Inc. (3)
9,220,774 Methods of treating cancer by administering anti-GPR49 antibodies		0	2012
9,221,906 Methods of inhibiting solid tumor growth by administering GPR49 antibodies		0	2012
9,221,907 Anti-GPR49 monoclonal antibodies		0	2012
BRISTOL-MYERS SQUIBB COMPANY (5)
* 2007/0166,704 Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways		12	2003
* 2006/0046,249 Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways		28	2003
7,259,002 Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof		0	2004
7,482,124 Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema		0	2006
* 2007/0009,945 Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof		2	2006
The Board of Trustees of the University of Illinois (2)
* 2009/0269,786 RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies		0	2009
* 2011/0229,909 RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies		0	2011
KYMAB LIMITED (5)
8,992,927 Targeting human NAV1.7 variants for treatment of pain		0	2014
8,986,694 Targeting human nav1.7 variants for treatment of pain		0	2014
9,062,105 Precision Medicine by targeting VEGF-A variants for treatment of retinopathy		1	2014
9,045,545 Precision medicine by targeting PD-L1 variants for treatment of cancer		0	2014
9,067,998 Targeting PD-1 variants for treatment of cancer		0	2014
VIB VZW (1)
* 6,479,280 Recombinant phages capable of entering host cells via specific interaction with an artificial receptor		3	1999
UNIVERSITE DE LORRAINE (1)
9,273,111 Therapeutic TREM-1 peptides		0	2011
VACCINEX, INC. (5)
* 2005/0158,323 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells		9	2004
* 2005/0266,425 Methods for producing and identifying multispecific antibodies		5	2004
7,807,168 Selection of human TNFα specific antibodies		0	2008
* 2009/0081,210 Methods of Killing Tumor Cells by Targeting Internal Antigens Exposed on Apoptotic Tumor Cells		4	2008
8,637,026 Anti-C35 antibody combination therapies and methods		0	2008
LIFE TECHNOLOGIES CORPORATION (8)
7,582,461 Kinase and phosphatase assays		5	2004
* 2005/0054,573 Kinase and phosphatase assays		19	2004
7,619,059 Bimolecular optical probes		1	2004
* 2005/0170,442 Bimolecular optical probes		22	2004
7,727,752 Kinase and phosphatase assays		4	2006
* 2007/0059,787 Kinase and phosphatase assays		2	2006
* 2010/0167,320 Compositions and Methods for Detecting and Quantifying Toxic Substances in Disease States		4	2009
8,067,536 Kinase and phosphatase assays		2	2010
Genentech, Inc. (4)
* 6,040,136 Enrichment method for variant proteins with altered binding properties		41	1997
* 2006/0292,554 Major coat protein variants for C-terminal and bi-terminal display		1	2005
* 2007/0117,126 SHOTGUN SCANNING		6	2006
8,685,893 Phage display		0	2008
ABBOTT LABORATORIES (2)
* 2009/0232,801 Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof		24	2008
9,371,374 HCV core lipid binding domain monoclonal antibodies		0	2013
BIOGEN MA INC. (16)
7,785,829 Nogo receptor binding protein		9	2004
* 2007/0059,793 Nogo receptor binding protein		8	2004
8,486,893 Treatment of conditions involving demyelination		3	2005
* 2006/0009,388 Treatment of conditions involving demyelination		13	2005
8,551,476 SP35 antibodies and uses thereof		3	2007
* 2010/0297,121 Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists		20	2008
* 2011/0123,553 Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination		7	2008
8,128,926 Sp35 antibodies and uses thereof		10	2009
8,058,406 Composition comprising antibodies to LINGO or fragments thereof		9	2009
* 2010/0015,131 Composition Comprising Antibodies to LINGO or Fragments Thereof		7	2009
8,425,910 Composition comprising antibodies to LINGO or fragments thereof		3	2011
8,609,407 Sp35 antibodies and uses thereof		3	2012
8,765,662 NOGO receptor binding protein		3	2012
9,068,992 Screening methods for identifying Sp35 antagonists		0	2013
8,932,821 NOGO receptor binding protein		0	2013
9,066,984 Sp35 antibodies and uses thereof		0	2013
Institut Pasteur (5)
7,427,469 Method of treating cytomegalovirus with DC-SIGN blockers		2	2003
7,419,789 Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers		0	2003
* 2006/0134,100 Dc-sign blockers and their use for preventing or treating viral infections		3	2003
* 2004/0197,330 Compositions comprising DC-SIGN blockers and methods of using DC-SIGN blockers for preventing or treating diseases of a mammal, including viral infections		0	2003
* 2009/0048,209 COMPOSITIONS COMPRISING DC-SIGN BLOCKERS AND METHODS OF USING DC-SIGN BLOCKERS FOR PREVENTING OR TREATING DISEASES OF A MAMMAL, INCLUDING VIRAL INFECTIONS		0	2008
MEDIMMUNE, INC. (1)
* 2003/0068,320 Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders		36	2002
PHYLOGICA LIMITED (10)
6,994,982 Isolating biological modulators from biodiverse gene fragment libraries		2	2000
7,270,969 Methods of constructing and screening diverse expression libraries		6	2003
* 2003/0215,846 Methods of constructing and screening diverse expression libraries		2	2003
7,803,765 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom		2	2004
* 2007/0031,832 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom		19	2004
* 2011/0218,118 PEPTIDE MODULATORS OF CELLULAR PHENOTYPE AND BI-NUCLEIC ACID FRAGMENT LIBRARY		1	2005
* 2005/0287,580 Isolating biological modulators from biodiverse gene fragment libraries		4	2005
8,575,070 Methods of constructing and screening libraries of peptide structures		0	2007
* 2009/0170,722 Methods of constructing and screening diverse expression libraries		3	2007
8,822,409 Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith		0	2008
Human Genome Sciences, Inc. (8)
7,429,646 Antibodies to human tumor necrosis factor receptor-like 2		2	2000
7,597,886 Tumor necrosis factor-gamma		6	2001
* 2002/0150,534 Tumor necrosis factor-gamma		11	2001
7,820,798 Tumor necrosis factor-gamma		1	2007
* 2007/0297,977 Tumor Necrosis Factor-Gamma		3	2007
7,824,675 Use of an antibody that binds human tumor necrosis factor receptor-like 2		1	2008
8,093,363 Tumor necrosis factor-gamma		0	2010
8,937,169 Human G-protein chemokine receptor HSATU68		0	2011
MEDIMMUNE LIMITED (1)
9,403,901 Anti-pseudomonas Psl binding molecules and uses thereof		0	2012
MEDIMMUNE, LLC (3)
* 2007/0025,990 Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders		17	2006
9,308,257 Protein formulation		0	2008
8,852,608 Antibodies against and methods for producing vaccines for respiratory syncytial virus		0	2009
SPECTRAL DIAGNOSTICS, INC. (1)
6,475,785 Single-chain polypeptides comprising troponin I N-terminal fragments and troponin C		2	1999
One Medimmune Way (1)
* 2010/0303,827 Protein Formulation		4	2008
CUREDM GROUP HOLDINGS, LLC (13)
8,211,430 Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions		2	2006
7,393,919 Peptides, derivatives and analogs thereof, and methods of using same		12	2006
* 2007/0087,971 Peptides, derivatives and analogs thereof, and methods of using same		6	2006
* 2009/0142,338 Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions		10	2007
8,785,400 Methods and compositions relating to islet cell neogenesis		0	2007
* 2009/0068,145 Methods and Compositions Relating to Islet Cell Neogenesis		5	2007
7,714,103 Peptides, derivatives and analogs thereof, and methods of using same		5	2008
* 2008/0300,190 PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME		7	2008
8,816,047 Compositions and methods of using proislet peptides and analogs thereof		0	2008
* 2011/0171,178 COMPOSITIONS AND METHODS OF USING PROISLET PEPTIDES AND ANALOGS THEREOF		3	2008
7,989,415 Peptides, derivatives and analogs thereof, and methods of using same		4	2009
8,383,578 Peptides, derivatives and analogs thereof, and methods of using same		1	2011
8,829,158 Peptides, derivatives and analogs thereof, and methods of using same		0	2013
Antigen Express, Inc. (1)
* 2010/0310,591 Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA		0	2010
MEDIMUNNE, LLC (1)
* 2010/0216,975 Framework-Shuffling Of Antibodies		1	2010
The Wistar Institute (1)
9,365,641 Compositions and methods for targeting stromal cells for the treatment of cancer		0	2013
UNIVERSITY OF ROCHESTER (6)
7,563,882 Polynucleotides encoding antibodies that bind to the C35 polypeptide		21	2003
* 2004/0063,907 Gene differentially expressed in breast and bladder cancer and encoded polypeptides		4	2003
7,750,125 Antibodies that bind to the C35 polypeptide		16	2007
* 2008/0089,886 Gene differentially expressed in breast and bladder cancer and encoded polypeptides		5	2007
7,968,688 Antibodies that bind to the C35 polypeptide		0	2009
7,879,990 Polynucleotides encoding antibodies that bind to the C35 polypeptide		0	2009
CYTOS BIOTECHNOLOGY AG (1)
* 2003/0091,593 In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles		22	2002
CODON DEVICES, INC. (1)
* 2007/0048,793 Compositions and methods for biocatalytic engineering		0	2006
SANOFI (5)
8,460,667 EPHA2 receptor antagonist antibodies		1	2007
* 2010/0047,257 ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER		10	2007
8,153,765 Anti-CD38 antibodies for the treatment of cancer		1	2007
* 2009/0304,710 NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER		8	2007
8,668,910 Antibodies that specifically bind to the EphA2 receptor		0	2010
Ikonisys, Inc. (3)
* 2006/0239,533 Method for detecting infectious agents using computer controlled automated image analysis		11	2002
7,885,449 System for detecting infectious agents using computer-controlled automated image analysis		0	2008
* 2008/0268,456 METHOD FOR DETECTING AND QUANTITATING MULTIPLE-SUBCELLULAR COMPONENTS		1	2008
NOVO NORDISK A/S (2)
9,000,127 Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)		0	2012
8,981,061 Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof		0	2012
SIAMAB THERAPEUTICS, INC. (2)
9,273,142 Glycan-interacting compounds		0	2013
9,416,194 Glycan-interacting compounds		0	2016
N.o slashed.AB Immunoassay, Inc. (1)
* 5,922,537 Nanoparticles biosensor		190	1996
BUNDESREPUBLIK DEUTSCHLAND LETZTVERTRETEN DURCH DAS ROBERT-KOCH-INSTITUT VERTRETEN DURCH SEINEN PRASIDENTEN (2)
8,318,905 Antibodies for depletion of ICOS-positive cells in vivo		0	2005
8,916,155 Method for the treatment of T cell mediated conditions by depletion of ICOS-positive cells in vivo		0	2012
UCB PHARMA S.A. (12)
* 2007/0269,428 Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity		8	2004
8,075,889 Antibody molecules having specificity for human IL-6		0	2006
* 2007/0154,481 Antibody Molecules Having Specificity For Human IL-6		13	2006
8,614,295 Antibody molecules having specificity for human OX40		0	2010
* 2010/0254,978 ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40		3	2010
9,067,995 Method to generate antibodies to ion channels		0	2010
8,926,977 Antibodies to the E1 extracellular loop of ion channels		0	2010
8,734,798 Function modifying NAv 1.7 antibodies		0	2010
* 2011/0135,662 FUNCTION MODIFYING NAv 1.7 ANTIBODIES		5	2010
8,486,662 DNA encoding antibody molecules having specificity for human IL-6		2	2011
9,096,668 Methods for making antibody molecules having specificity for human IL-6		0	2013
9,428,570 Antibody molecules having specificity for human OX40		0	2013
UCB, S.A. (1)
* 2006/0269,556 Mast cell activation using siglec 6 antibodies		0	2006
THE MCCOMB FOUNDATION, INC. (2)
8,946,381 Compositions and uses thereof for the treatment of wounds		0	2007
* 2010/0166,835 Compositions and uses thereof for the treatment of wounds		0	2007
FIVE PRIME THERAPEUTICS, INC. (1)
* 2007/0274,988 Kiaa0779, Splice Variants Thereof, and Methods of Their Use		0	2004
UCB BIOPHARMA SPRL (14)
* 2007/0148,172 Method for the treatment of inflammatory bowel disease		5	2004
7,736,635 Branched molecular scaffolds for linking polymer residues to biologically active moieties		0	2004
* 2007/0128,150 Branched molecular scaffolds for linking polymer residues to biologically active moieties		0	2004
8,129,505 Comb polymers		0	2006
* 2008/0220,005 Comb Polymers		0	2006
7,931,900 Method for the treatment of multiple sclerosis by inhibiting IL-17 activity		2	2008
8,691,233 Antibody molecules having binding specificity for human IL-13		0	2010
* 2010/0260,773 ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13		0	2010
9,045,529 Disulfide stabilized antibodies and fragments thereof		0	2011
8,580,265 Antibody molecules which bind IL-17A and IL-17F		1	2012
9,234,037 Method to generate antibodies to ion channels		0	2012
9,034,600 DNA encoding antibody molecules which bind IL-17A and IL-17F		0	2013
9,394,361 Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13		0	2014
8,986,954 1.7 antibodies		0	2014
VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW, a Belgium corporation (1)
* 2003/0148,508 Recombinant phages capable of entering host cells via specific interaction with an artificial receptor		1	2002
Millennium Pharmaceuticals, Inc. (8)
* 2004/0001,826 Glycoprotein VI and uses thereof		8	2001
7,101,549 Glycoprotein VI and uses thereof		5	2004
* 2004/0253,236 Glycoprotein VI and uses thereof		0	2004
* 2006/0216,291 Glycoprotein VI and uses thereof		4	2006
7,597,888 Glycoprotein VI and uses thereof		4	2006
* 2008/0050,380 Glycoprotein VI and uses thereof		6	2006
8,137,923 Glycoprotein VI and uses thereof		2	2010
* 2010/0261,200 Glycoprotein VI and Uses Thereof		0	2010
CHILDREN'S MEDICAL CENTER CORPORATION (4)
7,125,679 Methods to screen peptide libraries using minicell display		18	2002
* 2003/0044,863 Invasion complex and methods of targeting		3	2002
* 2004/0010,116 Minicell display and products therefrom		1	2003
* 2007/0072,221 Methods to screen peptide display libraries using minicell display		1	2006
TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (2)
7,294,701 Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same		2	2003
* 2004/0197,334 Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same		1	2003
ABBVIE INC. (61)
7,700,739 IL-12/p40 binding proteins		8	2006
7,612,181 Dual variable domain immunoglobulin and uses thereof		83	2006
8,691,224 Anti-Aβ globulomer 5F7 antibodies		0	2006
8,497,072 Amyloid-beta globulomer antibodies		0	2006
7,915,388 Interleukin-13 binding proteins		16	2007
8,455,626 Aβ conformer selective anti-aβ globulomer monoclonal antibodies		0	2007
8,962,803 Antibodies against the RGM A protein and uses thereof		0	2009
* 2010/0028,340 ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF		18	2009
9,029,508 Dual variable domain immunoglobulins and uses thereof		0	2009
8,323,651 Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof		4	2009
* 2010/0028,359 ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF		5	2009
9,109,026 Dual variable domain immunoglobulins and uses thereof		0	2009
9,035,027 Dual variable domain immunoglobulins and uses thereof		1	2009
* 2009/0311,253 Dual Variable Domain Immunoglobulins and Uses Thereof		38	2009
* 2009/0304,693 Dual Variable Domain Immunoglobulins and Uses Thereof		32	2009
8,258,268 Dual variable domain immunoglobulin and uses thereof		33	2009
* 2010/0047,239 Dual variable domain immunoglobulin and uses thereof		39	2009
8,822,645 Prostaglandin E2 dual variable domain immunoglobulins and uses thereof		9	2009
* 2010/0074,900 PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF		20	2009
* 2010/0233,079 Dual Variable Domain Immunoglobulins and Uses Thereof		17	2009
8,383,778 IL-1 binding proteins		1	2010
* 2010/0221,179 IL-1 Binding Proteins		8	2010
8,835,610 IL-17 binding proteins		6	2010
* 2010/0266,531 IL-17 BINDING PROTEINS		18	2010
8,629,257 IL-12/p40 binding proteins		0	2010
* 2011/0044,980 Dual Variable Domain Immunoglobulins and Uses Thereof		16	2010
8,623,358 Therapeutic DLL4 binding proteins		3	2010
8,586,714 Dual variable domain immunoglobulins and uses thereof		12	2010
* 2011/0091,372 Dual Variable Domain Immunoglobulins and Uses Thereof		13	2010
8,716,450 Dual variable domain immunoglobulins and uses thereof		13	2010
8,722,855 Dual variable domain immunoglobulins and uses thereof		10	2010
8,420,083 Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof		0	2010
* 2011/0212,094 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF		16	2010
* 2011/0135,664 MONOCLONAL ANTIBODIES AGAINST THE RGM A PROTEIN FOR USE IN THE TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION		6	2010
9,115,195 Therapeutic DLL4 binding proteins		0	2011
8,604,177 Interleukin-13 binding proteins		0	2011
* 2011/0165,066 INTERLEUKIN-13 BINDING PROTEINS		0	2011
8,987,419 Amyloid-beta binding proteins		0	2011
8,877,190 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies		0	2011
8,841,417 IL-1 binding proteins		0	2011
8,735,546 Dual variable domain immunoglobulins and uses thereof		10	2011
9,062,101 Amyloid-beta binding proteins		0	2011
9,046,513 Dual variable domain immunoglobulins and uses thereof		0	2011
9,394,363 Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof		0	2012
9,120,870 Dual specific binding proteins directed against IL-13 and IL-17		0	2012
9,067,996 Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof		0	2013
8,664,367 IL-I binding proteins		2	2013
9,359,430 Abeta conformer selective anti-Abeta globulomer monoclonal antibodies		0	2013
8,779,101 IL-17 binding proteins		1	2013
9,102,722 Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration		0	2013
9,163,093 Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof		0	2013
9,303,085 IL-1 binding proteins		0	2013
9,447,183 IL-1 binding proteins		0	2013
9,441,038 IL-1 binding proteins		0	2013
9,409,986 IL-1 binding proteins		0	2013
9,447,184 IL-1 binding proteins		0	2013
9,062,108 Dual specific binding proteins directed against IL-1 and/or IL-17		0	2014
9,045,551 Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof		0	2014
8,987,418 Dual specific binding proteins directed against IL-1β and/or IL-17		1	2014
9,394,360 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies		0	2014
9,365,643 Antibodies that bind to repulsive guidance molecule A (RGMA)		0	2014
BARROS RESEARCH INSTITUTE (1)
* 2005/0058,658 Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)		2	2004
UNIVERSITY OF MARYLAND, BALTIMORE (1)
* 2006/0068,379 Phage display of intact domains at high copy number		0	2005
SIEMENS HEALTHCARE DIAGNOSTICS INC. (2)
* 2003/0219,842 Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples		2	2003
7,732,159 Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples		0	2007
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (4)
7,393,534 Compositions and methods for immunotherapy of cancer and infectious diseases		0	2004
* 2005/0169,935 Compositions and methods for immunotherapy of cancer and infectious diseases		3	2004
8,257,714 Compositions and methods for immunotherapy of cancer and infectious diseases		0	2008
* 2009/0136,999 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASES		0	2008
NATIONAL UNIVERSITY OF SINGAPORE (2)
7,060,462 AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display		1	2001
* 2004/0076,976 Aopb gene, protein,homologs, fragments and variants thereof, and their use for cell surface display		0	2003
BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (3)
8,114,606 ARL-1 specific antibodies		0	2008
8,685,666 ARL-1 specific antibodies and uses thereof		0	2011
* 2011/0195,411 ARL-1 SPECIFIC ANTIBODIES AND USES THEREOF		1	2011
CRUCELL HOLLAND B.V. (5)
8,568,719 Antibodies against human respiratory syncytial virus (RSV) and methods of use		2	2010
* 2011/0076,268 Antibodies against human respiratory syncytial virus (RSV) and methods of use		2	2010
9,139,642 Anti-human respiratory syncytial virus (RSV) antibodies and methods of use		0	2011
9,365,638 Antibodies against human respiratory syncytial virus (RSV) and methods of use		0	2013
9,403,900 Anti-human respiratory syncytial virus (RSV) antibodies and methods of use		0	2014
SCHOLAR ROCK, INC. (1)
9,399,676 Compositions and methods for growth factor modulation		0	2015
LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (1)
9,259,467 Mammalian receptors as targets for antibody and active vaccination therapy against mold infections		0	2013
BIOXELL S.P.A. (1)
* 2009/0081,199 Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof		2	2008

* Cited By Examiner

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

---

Full Text

US Patent No: 5,516,637

Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage

---

 

Legal Events